WASHINGTON, D.C. – Yesterday, Senator Ed Markey (D-MA) and Representative Rosa DeLauro (CT-03) reintroduced the Flu Vaccine Act (S.2438/H.R.5092) — legislation that was originally introduced on Feb. 15, 2018, focused on conducting or supporting further comprehensive research for the creation of a universal influenza vaccine. The legislation calls for a total investment of $1 billion—$200,000,000 for each of fiscal years 2020 through 2024 for the National Institutes of Health (NIH).

“We commend the leadership and dedication of Senator Markey and Representative DeLauro to provide federal funding for universal influenza vaccine research. We need a better influenza vaccine as soon as possible, and the Flu Vaccine Act is an important step forward in reaching that goal,” said Bruce Gellin, M.D., M.P.H., Sabin’s president of Global Immunization and lead on influenza efforts. “The Sabin Vaccine Institute is committed to working with federal, foundation, and other partners to help move the world closer to ending the threat of influenza.”


Flu Vaccine Act

The Flu Vaccine Act is legislation to conduct or support comprehensive research for the creation of a universal influenza vaccine that could be administered once or twice and provide a lifetime of protection. Learn more about the bill here.


  • Seasonal flu causes an estimated 290,000 to 650,000 deaths worldwide, in the United States and other countries with health care systems.  
  • Each year, seasonal flu costs the United States more than $10 billion in direct medical costs and more than $87 billion in total economic costs.


About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a nonprofit with more than two decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on Twitter, @SabinVaccine. For more information on Sabin’s Influenzer Initiative and its work to accelerate the development of a universal influenza vaccine, visit www.influenzer.org and follow us on Twitter, @TheInfluenzers.

Media Contact
Mary Beth Woodin